Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment

European Journal of Endocrinology

Volumn 167, Issue 1, 2012, Pages 17-25

  Elenkova, Atanaska ^a   Shabani, Rabhat ^a   Kalinov, Krassimir ^b   Zacharieva, Sabina ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b NEW BULGARIAN UNIVERSITY   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FIBROSIS; HEART VALVE FIBROSIS; HEART VALVE REGURGITATION; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VALVULAR HEART DISEASE;

ADULT; ANTINEOPLASTIC AGENTS; BROMOCRIPTINE; CASE-CONTROL STUDIES; DOPAMINE AGONISTS; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; FIBROSIS; HEART VALVE DISEASES; HEART VALVES; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREVALENCE; PROLACTINOMA; PROSPECTIVE STUDIES;

EID: 84862736906     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0121     Document Type: Article

References (41)

1. Pritchett AM, Morrison JF, EdwardsWD, Schaff HV, Connolly HM& Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clinic Proceedings 2002 77 1280-1286. (doi:10.4065/77.12.1280)
2. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C & Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003 61 859-861. (Pubitemid 37174494)
3. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG & Dewey R Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004 63 301-304. (Pubitemid 38971130)
4. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR & Lang AE. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement Disorders 2004 19 656-662. (doi:10.1002/mds.20201)
5. Yamamoto M, Uesugi T & Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006 67 1225-1229. (doi:10.1212/01.wnl.0000238508.68593.1d)
6. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007 356 39-46. (doi:10.1056/NEJMoa054830)
7. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ & Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000 102 2836-2841. (doi:10.1161/01.CIR.102.23.2836)
8. Schade R, Andersohn F, Suissa S, Haverkamp W & Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007 356 29-38. (doi:10.1056/NEJMoa062222)
9. Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D & Schurad B. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clinical Neuropharmacology 2006 29 80-86. (doi:10.1097/00002826-200603000-00005)
10. Serratrice J, Disdier P, Habib G, Viallet F & Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiology in Review 2002 10 334-336. (doi:10.1097/00045415-200211000-00005)
11. Ciubotaru V, Poinsignon Y, Brunet-Bourgin F, Mestassi M & Rosenbaum D. Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature. La Revue de Medecine Interne 2004 25 310-314. (doi:10.1016/j.revmed.2004.01.004)
12. Saura J, Aguilar M & Alió J. Pleural effusion and constrictive pericarditis secondary to bromocriptine treatment. Neurologia 1991 6 331-333.
13. Debove P, Simon F, Vaylet F, Renard JL & L'Her P. Pleuropneumopathy caused by bromocriptine in a patient with Parkinson's disease. Review of the literature apropos of a new case. Annales de Medecine Interne 1998 149 167-171. (Pubitemid 28308738)
14. Kains JP, Hardy JC, Chevalier C & Collier A. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine. Acta Clinica Belgica 1990 45 306-310.
15. Boguszewski CL, Dos Santos CM, Sakamoto KS, Marini LC, de Souza AM & Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary 2012 15 44-49. (doi:10.1007/s11102-011-0339-7)
16. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. NIH Publication No. 04-5230; August 2004.
17. Mosteller RD. Simplified calculation of body surface area. New England Journal of Medicine 1987 317 1098. (doi:10.1056/NEJM198710223171717)
18. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ & American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. Journal of the American Society of Echocardiography 2003 16 777-802. (doi:10.1016/S0894-7317(03)00335-3)
19. Lancelotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano JL & on behalf of the European Association of Echocardiography. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. European Journal of Echocardiography 2010 11 307-332. (doi:10.1093/ejechocard/jeq031)
20. Chemla D, Castelain V, Provencher S, Humbert M, Simonneau G & Hervé P. Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest 2009 135 760-768. (doi:10.1378/chest.08-0904)
21. Devereux RB & Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977 55 613-618. (doi:10.1161/01.CIR.55.4.613)
22. Tan LC, Ng KK, Au WL, Lee RK, Chan YH & Tan NC. Bromocriptine use and the risk of valvular heart disease. Movement Disorders 2009 24 344-349. (doi:10.1002/mds.22228)
23. Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A, Grinspoon S, Lawson EA & Klibanski A. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical Endocrinology 2010 72 53-58. (doi:10.1111/j.1365- 2265.2009.03608.x)
24. Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F & Zelissen PM. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. European Journal of Endocrinology 2010 162 667-675. (doi:10.1530/EJE-09-0989)
25. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G & Serri O. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009 12 153-157. (doi:10.1007/s11102-008-0134-2)
26. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L & Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology 2008 159 1-5. (doi:10.1530/EJE-08-0213)
27. Herring N, Szmigielski C, Becher H, Karavitaki N & Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology 2009 70 104-108. (doi:10.1111/j.1365-2265.2008.03458.x)
28. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ & Pereira AM. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. Journal of Clinical Endocrinology and Metabolism 2008 93 3348-3356. (doi:10.1210/jc.2007-2658)
29. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P & Martin NM. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clinical Endocrinology 2010 73 369-374. (doi:10.1111/j.1365-2265.2010.03827.x)
30. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A & Martino E. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice 2008 62 1864-1869. (doi:10.1111/j.1742-1241.2008.01779.x)
31. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G & Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism 2008 93 3777-3784. (doi:10.1210/jc.2007-1403)
32. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A & Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology 2008 159 R11-R14. (doi:10.1530/EJE-08-0365)
33. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N & Millan MJ. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 2002 303 815-822. (doi:10.1124/jpet.102.039883)
34. Jähnichen S, Horowski R & Pertz H. Agonism at 5-HT2B receptors is not a class effect of the ergolines. European Journal of Pharmacology 2005 513 225-228. (doi:10.1016/j.ejphar.2005.03.010)
35. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B & Benjamin EJ. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). American Journal of Cardiology 1999 83 897-902. (doi:10.1016/S0002-9149(98)01064-9)
36. Jones EC, Devereux RB, Roman MJ, Liu JE, Fishman D, Lee ET, Welty TK, Fabsitz RR & Howard BV. Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study). American Journal of Cardiology 2001 87 298-304. (doi:10.1016/S0002-9149(00)01362-X)
37. Freed LA, Benjamin EJ, Levy D, Larson MG, Evans JC, Fuller DL, Lehman B & Levine RA. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. Journal of the American College of Cardiology 2002 40 1298-1304. (doi:10.1016/S0735- 1097(02)02161-7)
38. Rasmussen VG, Ostergaard K, Dupont E & Poulsen SH. The risk of valvular refurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Movement Disorders 2011 26 801-806. (doi:10.1002/mds.23470)
39. Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G & Maroteaux L. Function of the 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature Medicine 2002 8 1129-1135. (doi:10.1038/nm764)
40. Königshoff M, Dumitrascu R, Udalov S, Amarie OV, Reiter R, Grimminger F, Seeger W, Schermuly RT & Eickelberg O. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax 2010 65 949-955. (doi:10.1136/thx.2009. 134353)
41. Kaumann AJ & Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacology & Therapeutics 2006 111 674-706. (doi:10.1016/j.pharmthera.2005.12.004)